



The European Agency for the Evaluation of Medicinal Products
Human Medicines Evaluation Unit

TELEFAX MESSAGE

DATE: 21 September, 1998 REF: OF - PSUR 3 (O/Z)
EMEA-H-AH-njro-28499-1998

TO: Ms Jenny Shaw-Stewart PHONE: 01276 853 018
Lilly Research Centre Limited FAX: 01276 853 378

FROM: Mr Tony Humphreys PHONE: +44.171.418.8583
Senior Scientific Administrator FAX: +44.171.418.8551

RE: OLANSEK/ZYPREXA - Third Periodic Safety Update Report covering the
period from 26 September 1997 to 31 March 1998

CC: Dr Toivonen
Ms Priya Bahri, EMEA Pharmacovigilance Sector

Number of Pages (including cover sheet): 2

Message:

Dear Ms Shaw-Stewart,

We refer to the documentation submitted for Olansek and Zyprexa concerning:

- Third periodic safety update reports covering the period from 26 September 1997 to 31 March 1998.

We inform you that the CPMP, during its meeting held from 15 - 17 September 1998, concluded that the areas of concern after the first two PSUR's (ventricular arrhythmias, haematological toxicity, liver toxicity and interactions) give no new signals or concern in the present PSUR. Based on the present PSUR, the risk/benefit remains unchanged.

A Type II Variation application should be submitted to include "fever" under the section Undesirable effects in the SPC and PIL.

Fourth PSUR:

Hyperglycaemia and disorders in glucose metabolism should be closely monitored and reported in the forthcoming PSUR's. In addition, the time schedule for submitting the planned in-depth review of cases related to disorders of blood glucose metabolism should be provided without delay. The full analysis should be submitted before the fourth PSUR.

All serious reactions should be described adequately and not only quoted in the body system review. The incidence of serious unlisted adverse reactions should be compared with

IF THIS FAX IS ILLEGIBLE OR INCOMPLETE, PLEASE CALL THE PHONE NUMBER ABOVE
Confidential

7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8551
E-Mail: mail@emea.oudra.org http://www.oudra.org/emea.html

SPV only
1 WEEK
MMSY
6602
Bun

experience based on previous PSUR's, especially for the areas of concern (glycaemic disorders, blood dyscrasias, hepatic effects, cardiovascular effects, Neuroleptic Malignant Syndrome).

LSM
PSUR
LSM
PSUR
LSM
PSUR

- The mechanisms for the reported cases of coma (n=7) should be elucidated upon.

Olanzapine is not authorised for use in children. However, twenty adverse reactions have been reported. Paediatric use and adverse reactions should be monitored closely for the next PSUR and justifications for treatment should be provided.

Neuroleptic Malignant Syndrome, coma, blood dyscrasias, alopecia, fever and priapism should also be monitored closely for the next PSUR as well as the continued close monitoring of cardiovascular adverse events, especially regarding corrected QT interval prolongation, arrhythmias, syncope and sudden death.

Additional Studies:

The analysis of effects of olanzapine on QT_c included in this PSUR should be extended to include:

1. The percentage of patients with absolute QT_c greater than 500 msec;
2. The percentage of patients with individual increase in QT_c between 30-60 msec and > 60 msec;
3. QT_c dispersion: dispersion > 100 msec and change in dispersion of more than 100%. The analysis should be accompanied by full study reports related to electrophysiological effects.

complex is complete

APPENDICES

Due to inconsistent effects on repolarisation and QT_c interval observed in the *in vitro* and *in vivo* animal studies and clinical studies, the CPMP have requested a study of the effects of olanzapine and metabolites on human myocardial ion channels as outlined in the "Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products" (CPMP/986/96).


Bin
CAMS

As with the request concerning blood glucose disorders, you are asked to supply the time schedule for submitting this extended analysis including full study reports together with a time schedule and protocol for the myocardial ion channel study without delay.

TIMETABLE
i pattern

If you have any queries regarding the above, please do not hesitate to contact us, or the Rapporteur Dr Markku Toivonen.

Yours sincerely,


Tony Humphreys